Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,107 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vein Disease Clear all
Completed No phase listed Observational Accepts healthy volunteers

Non-Invasive Management of Chronic Venous Insufficiency

NCT00950378
View directory record Official record
Conditions
Venous Insufficiency
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
40 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Not applicable Interventional Results available

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

NCT02245516
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Beverly Hills, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Results available

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

NCT00439725
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Not applicable Interventional

Pulmonary Vein Isolation in Athletes

NCT03226847
View directory record Official record
Conditions
Athletes, Atrial Fibrillation, Catheter Ablation
Interventions
Pulmonary Vein Isolation
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 6, 2026, 10:52 PM EDT
Completed No phase listed Observational

Outpatient Office Based Endovascular Procedures

NCT04054440
View directory record Official record
Conditions
Chronic Venous Insufficiency, Peripheral Arterial Disease, Dialysis Access Malfunction, Arterio-venous Fistula, Thoracic Outlet Syndrome, Vertebral Artery Insufficiency, Varicose Veins
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
26,000 participants
Timeline
2014 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 6, 2026, 10:52 PM EDT
Not listed Not applicable Interventional

Enhanced Ultrasound Treatment of Chronic Wounds With Monitoring of Healing and Quality of Life Outcomes

NCT03041844
View directory record Official record
Conditions
Diabetic Foot Ulcer, Venous Ulcer
Interventions
Low Frequency, Low Intensity Ultrasound, Sham Applicator
Device
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03093701
View directory record Official record
Conditions
Retinal Vein Occlusion, Macula Edema
Interventions
TLC399 (ProDex)
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

NCT03077165
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
S42909 100 mg, S42909 200 mg, S42909 400 mg, S42909 800 mg, S42909 1200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Ilkos Therapeutic Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Carlsbad, California • Carmichael, California • Castro Valley, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 6, 2026, 10:52 PM EDT
Completed No phase listed Observational

Anatomic Outcomes Following Ozurdex Injections

NCT01282411
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Not listed
Lead sponsor
Barnes Retina Institute
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

NCT00055692
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Not applicable Interventional

Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS)

NCT02907411
View directory record Official record
Conditions
Lipedema
Interventions
Quadrivas Therapy
Other
Lead sponsor
University of Arizona
Other
Eligibility
19 Years to 70 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer

NCT02850536
View directory record Official record
Conditions
Liver Metastases
Interventions
anti-CEA CAR-T cells
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 6, 2026, 10:52 PM EDT
Terminated No phase listed Observational

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

NCT05819112
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
14,799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 6, 2026, 10:52 PM EDT
Not listed Phase 4 Interventional

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02342444
View directory record Official record
Conditions
Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
Interventions
Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 100 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 6, 2026, 10:52 PM EDT
Not listed No phase listed Observational

Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer

NCT02507180
View directory record Official record
Conditions
Pregnancy, Deep Vein Thrombosis
Interventions
LEFt clinical decision rule
Other
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
16 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 6, 2026, 10:52 PM EDT
Not listed Not applicable Interventional

The Evaluation of OrCel for the Treatment of Venous Ulcers

NCT00270972
View directory record Official record
Conditions
Venous Insufficiency, Leg Ulcer
Interventions
Bilayered Cellular Matrix (OrCel)
Device
Lead sponsor
Ortec International
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Montgomery, Alabama • Phoenix, Arizona • Castro Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2006 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Phase 3 Interventional

SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed

NCT00002551
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, levamisole hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2008
U.S. locations
35
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2007 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Results available

Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

NCT01231373
View directory record Official record
Conditions
Varicose Veins
Interventions
polidocanol injectable foam, 0.125%, polidocanol injectable foam, 0.5%, polidocanol injectable foam, 1.0%, Vehicle
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
12
States / cities
Dothan, Alabama • San Diego, California • Lafayette, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 6, 2026, 10:52 PM EDT
Completed Not applicable Interventional Results available

Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers

NCT01549860
View directory record Official record
Conditions
Venous Insufficiency, Venous Reflux, Lower Extremity Ulcer
Interventions
MIST Therapy
Device
Lead sponsor
Celleration, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 6, 2026, 10:52 PM EDT
Not listed No phase listed Observational

Keller Prehospital Ultrasound Study

NCT01074112
View directory record Official record
Conditions
Ultrasonography, Multiple Trauma, Kidney Calculi, Aortic Aneurysm, Abdominal, Pregnancy, Catheterization, Venous
Interventions
EFAST exam, Pelvic Ultrasound, Ultrasound Guided Vascular Access, Focused Ultrasound Scan, Cardiac Ultrasound
Device · Procedure
Lead sponsor
Keller Fire Rescue
Government
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Keller, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2010 · Synced Oct 6, 2026, 10:52 PM EDT
Active, not recruiting No phase listed Observational

Real-World Effectiveness of Amniotic Membrane Allografts Versus Standard Wound Care in DFU, VLU, and PU

NCT07223281
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Interventions
Not listed
Lead sponsor
Legacy Medical Consultants
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Colorado Springs, Colorado • Clinton Township, Michigan • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 6, 2026, 10:52 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05161481
View directory record Official record
Conditions
Hypertension, Portal
Interventions
Avenciguat (BI 685509), Placebo matching Avenciguat (BI 685509)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 6, 2026, 10:52 PM EDT
Active, not recruiting Not applicable Interventional

Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)

NCT03250247
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome
Interventions
Stents
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
29
States / cities
Orange, California • San Francisco, California • New Haven, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 6, 2026, 10:52 PM EDT